SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Director/PDMR Dealing

11 Nov 2022 15:07

RNS Number : 1974G
Frontier IP Group plc
11 November 2022
 

RNS

AIM: FIPP

11 November 2022

 

 

 

Frontier IP Group plc

 

("Frontier IP" or the "Group")

 

Director/PDMR Dealing

 

Frontier IP, a specialist in commercialising intellectual property, announces that Andrew Richmond, Non-Executive Chairman, has, between 9 November 2022 and 11 November 2022, sold a total of 150,000 ordinary shares of 10p each ("Ordinary Shares") in Frontier IP, at an average price of 69.0 pence per share.

 

Following the sale, Andrew Richmond has an interest in 850,000 Ordinary Shares, representing 1.55% of the Group's issued share capital.

 

The notification below, which has been made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Andrew Richmond

 

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

 

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

 

b)

LEI

213800BRYUKQPJWKJ312

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 10p

 

ISIN: GB00B63PS212

 

b)

Nature of the transaction

Sale of Ordinary Shares

 

 

c)

Price(s) and volume(s)

 

 

 

 

 

 

 

 

 

 Price(s)

Volume(s)

71.25 pence

30,000 shares sold (9 November 2022)

68.5 pence

50,000 shares sold (10 November 2022)

68.2 pence

25,000 shares sold (10 November 2022)

68.5 pence

45,000 shares sold (11 November 2022)

d)

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregate amount

 

 

 

150,000

 

Average price of 69 pence per share

 

£103,500

e)

Date of the transactions

9 November 2022, 10 November 2022 and 11 November 2022

 

f)

Place of the transaction

London Stock Exchange (AIM)

 

 

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

 

M: 07464 546 025

andrew.johnson@frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPGAUGUPPGAG
Date   Source Headline
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.